The company reports that its GanedenBC30 probiotic improved stool consistency in mice with colitis.
Ganeden Biotech (Cleveland) reports that its GanedenBC30 probiotic improved stool consistency in mice with colitis. The research, published in the journal Gut Pathogens, was performed by researchers at the Penn State College of Medicine (Hershey, PA).
Colitis is an inflammatory condition of the colon, often resulting in diarrhea symptoms. The condition affects an estimated 500,000 people annually, according to the Centers for Disease Control and Prevention.
In the recent study on Ganeden’s proprietary strain of Bacillus coagulans, mice were induced with Clostridium difficile colitis and assigned to the probiotic or a vehicle treatment of saline for 15 days. The primary measure, assessed on day 16, was stool consistency.
At the end of the study, 23.8% of mice in the GanedenBC30 group exhibited normal stool consistency compared to 0.0% of mice in the vehicle group.
Ganeden Biotech has expressed interest in the Penn State study as it suggests potential for the probiotic’s successful use for colitis in humans.
While colitis is often treated with antibiotics, lead researcher Leo Fitzpatrick, PhD, says the study suggests a potential for alternative probiotic support for the condition.
“Some previous clinical studies focused on combined treatment with vancomycin and probiotics,” says Fitzpatrick. “But in this study, administering only GanedenBC30 to Clostridium difficile infected mice resulted in an improvement in the consistency of their stool and reduction in the severity of the disease. This information is particularly helpful and potentially applicable for individuals going into the hospital or a nursing home, where the likelihood of obtaining this disease is higher.”